Veterinary Resources
R E S U L T S
Trial Data. Revealed.
ECI® was first evaluated in the BASE study, followed by the pivotal randomized BASER trial, which led to USDA-Center for Veterinary Biologics regulatory approval. A third study, ASCENT, introduced a dose of chemotherapy between surgery and ECI® which demonstrated improved 1-year survival rates in the interim analysis on the first cohort of dogs (n=21).
C.A.S.E ..S.T.U.D.I.E.S
Real Patients. Real Outcomes.
W E B I N A R S
Veterinary Education. On Demand.
Using ECI® in a Multimodal Treatment Strategy
In this presentation, we review a study that examined the safety and efficacy of combining carboplatin with ECI®, a vaccine-enhanced adoptive cell therapy, as treatment for dogs with newly-diagnosed osteosarcoma, with a particular focus on the use of a single carboplatin dose.
Treating Canine Cancer with Killer T Cells
Recent advances in the fourth pillar of cancer treatment—immunotherapy—suggest that the immune system may be our best tool to cure more cancers. Watch this webinar to learn how the move to an immunotherapeutic approach to treat canine cancer can make a difference for your patients and their families.
Changing the Way Veterinarians Treat Canine Cancer
Pet owners and their families are urgently looking for new and better options to prolong their companion’s life and improve the quality of life. How can veterinarians help these dogs and these families address this reality? Watch this webinar to learn more about the limitations of traditional treatments for canine osteosarcoma (amputation and chemotherapy) and how cutting edge cancer immunotherapies are opening new frontiers in veterinary medicine.
Can We Treat Canine Osteosarcoma Without Chemotherapy?
Jeffrey Bryan, DVM, DACVIM (O) and Brian Flesner, DVM, DACVIM (O) discuss immunotherapy, including adoptive T cell therapies for dogs. The hosts also review published results of an innovative treatment for osteosarcoma that included no radiation or
chemotherapy.
Testimonials
“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially and on average, based on that median survival. I will also point out that every single piece of the ELIAS immunotherapy process is extremely well supported in scientific literature.”